Table 2.
Fluconazole, caspofungin and amphotericin B susceptibility results for isolates belonging to the four most common Candida spp.a
| Candida spp. (no. tested) / antifungal drug | MIC (µg/ml) | Resistant isolates (%) | ||
|---|---|---|---|---|
| Range | MIC50 | MIC90 | ||
| Candida albicans (102) | ||||
| Fluconazole | ≤ 0.125– > 256 | 0.25 | 0.5 | 2 |
| Caspofungin | ≤ 0.008–0.5 | 0.03 | 0.125 | 0 |
| Amphotericin B | ≤ 0.125–1.0 | 0.5 | 1.0 | 0 |
| Candida parapsilosis (54) | ||||
| Fluconazole | ≤ 0.125–2.0 | 0.5 | 1.0 | 0 |
| Caspofungin | 0.03–1.0 | 0.5 | 1.0 | 0 |
| Amphotericin B | 0.125–1.0 | 0.5 | 1.0 | 0 |
| Candida tropicalis (20) | ||||
| Fluconazole | 0.5–4.0 | 1.0 | 2.0 | 0 |
| Caspofungin | ≤ 0.008–0.125 | 0.06 | 0.06 | 0 |
| Amphotericin B | 0.125–1.0 | 1.0 | 1.0 | 0 |
| Candida glabrata (16) | ||||
| Fluconazole | 2.0–32 | 8.0 | 32 | 0 |
| Caspofungin | 0.03–0.5 | 0.06 | 0.125 | 0 |
| Amphotericin B | 0.25–1.0 | 1.0 | 1.0 | 0 |
aMICs were interpreted according to latest species-specific clinical breakpoints as established by the Clinical and Laboratory Standards Institute (CLSI) [13]